|
|||||
![]() |
|
Media broadcasting company Sinclair (NASDAQ:SBGI) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 5.4% year on year to $784 million. Next quarter’s revenue guidance of $764 million underwhelmed, coming in 3.6% below analysts’ estimates. Its non-GAAP loss of $0.94 per share was 12.7% above analysts’ consensus estimates.
Is now the time to buy SBGI? Find out in our full research report (it’s free).
Sinclair’s second quarter results disappointed investors, with the stock declining sharply after both revenue and adjusted EBITDA missed Wall Street’s expectations. Management attributed the underperformance primarily to continued softness in distribution revenue, as subscriber growth from virtual multichannel video programming distributors (MVPDs) lagged projections. Advertising trends remained mixed, with certain categories pressured by macroeconomic and tariff-related challenges, though management did highlight some stabilization in core advertising late in the quarter. CEO Chris Ripley acknowledged the ongoing uncertainties, stating, “Several large categories remain hampered by macroeconomic and tariff-related uncertainty, but we have started to see signs of improvement over the past several weeks.”
Looking ahead, Sinclair’s guidance reflects caution, with management pointing to ongoing headwinds in both distribution and advertising revenue. CFO Narinder Sahai emphasized the impact of recent station divestitures and slower than anticipated subscriber trends, particularly in the virtual MVPD segment. While there are early signs of stabilization in some advertising categories, Ripley noted that “overall visibility remains below historical levels given the uncertainty,” and the company expects the upcoming quarters to remain challenged. Management plans to focus on operational efficiency, cost discipline, and monetizing assets within its Ventures portfolio to help offset these pressures.
Sinclair’s management cited a mix of industry-specific and broader economic factors affecting both the quarter’s results and the outlook for the rest of the year.
Management expects persistent industry headwinds, asset sales, and evolving regulatory dynamics to shape Sinclair’s near-term performance and profitability.
In the coming quarters, the StockStory team will monitor (1) Sinclair’s ability to stabilize and grow core advertising revenues as economic and tariff-related uncertainties persist; (2) the pace and financial impact of new M&A activity enabled by regulatory changes; and (3) progress in monetizing Ventures portfolio assets and shifting toward majority-owned, operationally controlled businesses. The execution of these priorities will be key to navigating a challenging industry environment.
Sinclair currently trades at $16.00, up from $14.15 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Aug-19 | |
Aug-19 | |
Aug-19 | |
Aug-18 | |
Aug-18 | |
Aug-18 | |
Aug-15 | |
Aug-14 | |
Aug-13 | |
Aug-13 | |
Aug-13 | |
Aug-12 | |
Aug-12 | |
Aug-12 | |
Aug-11 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite